Published: May 17, 2026 · Last updated: May 17, 2026
- More than 1 in 3 adults with diabetes will develop diabetic retinopathy, making it the leading cause of blindness in working-age adults in the United States (NEI, 2024)
- A 10-minute dilated eye exam catches diabetic retinopathy in its earliest, fully treatable stage; early treatment lowers the risk of severe vision loss by roughly 95% (NEI, 2024)
- Fewer than half of US adults with diabetes get the recommended annual dilated eye exam on schedule, which is the single biggest preventable factor in diabetes-related blindness (CDC, 2024)
The most common preventable cause of blindness in American adults is not glaucoma. It is not macular degeneration. It is diabetic retinopathy, and the test that catches it in time is one most people with diabetes skip every other year.
The early stage of diabetic retinopathy has no symptoms. None. Your vision feels fine. The blood vessels in the back of your eye are already weakening. By the time you notice blurry vision or floaters, you are usually in the moderate or advanced stage where treatment is harder and vision loss may already be permanent. A 10-minute dilated exam is the difference between a manageable condition and a wheelchair-and-cane future.
What Happens to Your Eyes With Diabetes:
Chronically high blood sugar damages the tiny blood vessels feeding the retina, the light-sensitive tissue at the back of the eye. Over years, those vessels leak fluid, swell, and eventually grow abnormal new vessels that can bleed into the eye or pull the retina off the back wall.
The stages go in order: mild nonproliferative retinopathy (small bulges in vessels), moderate (some vessels close), severe (many vessels close, retina signals for new growth), and proliferative (abnormal new vessels grow, the most dangerous stage). Each stage has clear features visible on a dilated exam (NEI, 2024).
A separate but related problem is diabetic macular edema, where fluid swells the macula (the part of the retina handling sharp central vision). Macular edema can happen at any stage and is the most common cause of vision loss in diabetic retinopathy.
The 1-in-3 Number (And Who Gets It Worst):
About 9.6 million Americans have some form of diabetic retinopathy and roughly 1.8 million have vision-threatening disease (CDC, 2024). The longer someone has had diabetes, the higher the risk. After 20 years with type 1 diabetes, nearly all patients show some retinopathy. After 20 years with type 2, about 60 percent do.
Risk is highest in people whose blood sugar has run uncontrolled, whose blood pressure is elevated, who smoke, and who are pregnant with diabetes. Hispanic and Black Americans with diabetes have higher rates of advanced retinopathy, partly tied to screening access and partly to disease severity.
The mortality of the eye disease itself is zero. The vision loss is what changes someone's life. Driving stops. Reading stops. Independence narrows. That is what early detection is preventing.
How the Annual Dilated Exam Works:
An ophthalmologist or optometrist puts dilating drops in each eye. After 20 minutes the pupils are wide enough to allow a panoramic view of the retina. The provider examines each retina with a lighted scope, often photographing the back of the eye for record-keeping (Mayo Clinic, 2024).
The exam takes about 10 minutes once the drops have worked. Pupil dilation lasts 4 to 6 hours, during which bright light is uncomfortable and reading up close is blurry. Most patients have someone drive them home or stay at the office until the drops wear off.
A newer alternative for low-risk patients is retinal imaging, a wide-angle photograph of the retina that does not require dilation. Imaging is fine for routine screening but misses some peripheral findings that a full dilated exam catches. Patients with established retinopathy or known macular issues should stick with the dilated exam.
What Treatment Looks Like (And Why Early Matters):
In the mild and moderate stages, treatment is tighter blood sugar control plus closer monitoring (every 3 to 6 months instead of yearly). No injections, no surgery. Vision usually stays stable for years.
In the severe and proliferative stages, treatment shifts to intravitreal injections of anti-VEGF medication (Lucentis, Eylea, Avastin), laser photocoagulation, or vitrectomy surgery for advanced bleeding. Anti-VEGF injections work, but they require visits every 4 to 8 weeks for months or years, and they cost up to $2,000 per injection.
Treatment in the early stages is conservative and cheap. Treatment in the late stages is invasive and expensive. The 95 percent reduction in severe vision loss with early detection is the gap between those two realities.
To your health,
Ageless Coach
Age Strong. Live Long.
Trusted Sources Behind This Article
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.
Frequently Asked Questions
Want one verified-science article like this every week?
Get Better Health, Weekly